Description: Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
Home Page: www.krystalbio.com
2100 Wharton Street
Pittsburgh,
PA
15203
United States
Phone:
412 586 5830
Officers
| Name | Title |
|---|---|
| Mr. Krish S. Krishnan M.B.A., M.S. | Founder, Chairman, President & CEO |
| Ms. Suma M. Krishnan | Founder, President of R&D and Director |
| Ms. Kathryn A. Romano CPA | Executive VP & Chief Accounting Officer |
| Mr. John Thomas | General Counsel & Corporate Secretary |
| Mr. John Karakkal | Vice President of North American Sales & Marketing |
| Ms. Christine Wilson | Head of U.S. Sales & Marketing |
| Dr. Stephane Paquette Ph.D. | Vice President of Corporate Development |
| Mr. Josh Suskin | Director of Human Resources & Operations |
| Mr. Laurent Goux | Senior VP & GM of Europe |
| Mr. David Chien | Senior Vice President of Clinical Development |
Exchange: STU
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 32.1543 |
|---|---|
| Trailing PE: | 99.9704 |
| Price-to-Book MRQ: | 5.8063 |
| Price-to-Sales TTM: | 20.3635 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 229 |